U.S. markets closed

Global Cord Blood Corporation (CO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
4.7900-0.0100 (-0.21%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close4.8000
Open4.8300
Bid4.7500 x 2200
Ask4.8200 x 2200
Day's Range4.7000 - 4.8600
52 Week Range2.5400 - 4.9800
Volume649,502
Avg. Volume261,786
Market Cap582.229M
Beta (5Y Monthly)0.37
PE Ratio (TTM)16.35
EPS (TTM)0.2930
Earnings DateFeb 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 31, 2018
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
62% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Global Cord Blood Corporation Announces Receipt of Unsolicited Non-Binding Acquisition Proposal
    PR Newswire

    Global Cord Blood Corporation Announces Receipt of Unsolicited Non-Binding Acquisition Proposal

    Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that its board of directors (the "Board") has received a non-binding proposal letter from Alternate Ocean Investment Company Limited ("Alternate Ocean"), a wholly-owned subsidiary of Haitong International Securities Group Limited (Stock Code: 665.HK), pursuant to which Alternate Ocean, acting on behalf of certain funds and/or entities that it manages and/or advises, proposes to acquire all of the outstanding ordinary shares of the Company for US$5.00 per ordinary share in cash, subject to certain conditions.

  • ACCESSWIRE

    Global Cord Blood Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Global Cord Blood Corp. (NYSE:CO) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on February 25, 2021 at 8:00 AM Eastern Time.

  • Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2021
    PR Newswire

    Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2021

    Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the third quarter and first nine months of fiscal 2021, ended December 31, 2020.